- 11/05/2019
- eisai transfers rights to receive royalties outside of japan for ezh2 inhibitor tazemetostat to royalty pharma
- 10/22/2019
- biogen plans regulatory filing for aducanumab in alzheimer’s disease based on new analysis of larger dataset from phase 3 studies
- 10/19/2019
- eisai china successfully held "2019 ads beijing "
- 10/15/2019
- new drug approval for fycompa® for adjunctive treatment of partial onset seizures in china
- 10/13/2019
- eisai china inc. actively participated in "the 2nd large-scale alzheimer-disease-month memory walk campaign"
- 09/30/2019
- eisai and nichi-iko enter into collaboration agreement for generic pharmaceutical business in china
- 09/26/2019
- eisai and tokio marine nichido enter into business alliance for co-existence and prevention of dementia
- 09/26/2019
- eisai and fronteo to launch coroban® tumbling and falling prediction system for inpatients
- 09/24/2019
- eisai to present abstracts on oncology products and pipeline at esmo 2019 congress
- 09/20/2019
- eisai and meiji announce parkinson’s disease treatment equfina® tablets (safinamide mesilate) approved in japan
